(Q34608654)

3 August 2017

Insurance coverage policies for personalized medicine (English)

1 reference

3 August 2017

personalized medicine

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Susanne B Haga

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

30 October 2012

1 reference

Journal of personalized medicine

3 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

201-216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

13 June 2020

copyright license

start time

30 October 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Personalizing medicine with clinical pharmacogenetics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Public perspectives about pharmacogenetic testing and managing ancillary findings

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Health technology assessment and private payers' coverage of personalized medicine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Survey of US public attitudes toward pharmacogenetic testing

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Personalized medicine: factors influencing reimbursement.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Gene-expression signatures in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Pharmacogenomics, evidence, and the role of payers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

HLA-B*5701 clinical testing: early experience in the United States

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251376

Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients.

7 July 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Payer perspectives on pharmacogenomics testing and drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

The evidence dilemma in genomic medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

The long and winding road to warfarin pharmacogenetic testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Putting pharmacogenetics into practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FJPM2040201

Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs

21 January 2018

1 reference

12 December 2020

Coverage options for promising technologies: Medicare's 'coverage with evidence development'

1 reference

12 December 2020

Transplant vasculopathy is associated with increased AlloMap gene expression score

1 reference

12 December 2020

Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression

1 reference

12 December 2020

Personalized medicine and disruptive innovation: implications for technology assessment

1 reference

12 December 2020

Application of a pharmacogenetic test adoption model to six oncology biomarkers

1 reference

12 December 2020

Identifiers

DOI

10.3390/JPM2040201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25562360%20AND%20SRC:MED&resulttype=core&format=json